Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath, is an assistant professor in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center

Dr Jen on the Efficacy of an All-Oral, Revumenib-Containing Regimen in AML

“We had a cohort of 21 patients, one-third of which [had] 

 rearrangements. [In this population], the overall response rate was high, [at 86%]. The complete response [CR]/CR with partial hematologic recovery rate was also [86%].”

Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath, an assistant professor in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discussed findings from the phase 2 SAVE trial (NCT05360160) evaluating revumenib (Revuforj) plus decitabine, cedazuridine, and venetoclax (Venclexta) in patients with newly diagnosed acute myeloid leukemia.

Videos

Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath, discusses the efficacy of revumenib plus decitabine, cedazuridine, and venetoclax in newly diagnosed AML.

Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath

Articles

Dr Jen on the Efficacy of an All-Oral, Revumenib-Containing Regimen in AML